CSIRO warns of superbug-led ‘catastrophe’: Does Invion (ASX: IVX) have an answer?

March 02, 2023 05:55 PM AEDT | By Ankit Sethi
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp


  • In a recent report and accompanying blog, CSIRO has talked about the threat that superbugs pose to humans
  • Antimicrobial resistance is being fuelled by factors like climate change, which let superbugs to thrive in warm temperatures
  • Invion Limited, an ASX listed entity, is leading the research and development of PhotosoftTM technology
  • The tests have found that PhotosoftTM technology has the potential to kill a wide variety of superbugs

One of the hardly ever discussed fallouts of rising global temperature is the rise of superbugs. Superbugs can be understood as a strain that has resistance to antibiotics. In its recently released report on the subject-matter, the Commonwealth Scientific and Industrial Research Organisation (CSIRO) – an Australian government agency engaged in scientific research -- has talked about the ‘silent pandemic’ facing the human population due to antimicrobial resistance (AMR).

The report by CSIRO, titled ‘Curbing antimicrobial resistance’, stresses on ‘technology-powered’ approach to overcoming the situation. In this light, Australia’s listed life sciences company -- Invion Limited (ASX: IVX) -- asserts to be working toward solutions. Let us know more.

The CSIRO report

CSIRO has stated that climate change is fuelling the spread of AMR, and there is lack of new treatments for effective diagnosis and prevention. It also talks about how embracing of technology and a human-driven approach can lead to improvements. In an accompanying blog, CSIRO has also warned that next time anyone takes an antibiotic drug, it ‘may not work’. Bacteria, it says, has developed resistance to these traditional drugs.

Superbugs are said to be ‘thriving’ in warm and wet conditions, and there needs to be ‘modern solutions’, including point-of-care diagnosis, to manage and prevent AMR. The detailed report also asserts that AMR can disrupt any progress on the Sustainable Development Goals (SDG).

Invion’s PhotosoftTM technology shows effectiveness against superbugs

Invion is a listed entity leading the global R&D of PhotosoftTM technology to help support the treatment of a range of infectious diseases and ailments like cancer.

Last year, the company released promising early test results of the technology on infectious diseases. These included in vitro tests by the Australian Centre for Antimicrobial Resistance Ecology (ACARE) that demonstrated Photosoft’s activity against multiple strains of methicillin-resistant Staphylococcus aureus (MRSA) bacteria. The bacteria is a type of superbug, which is antibiotic resistant and difficult to treat.

Notably, ACARE also found that compounds of Photosoft were effective against other bacteria and fungi.

Data source: IVX update

For the PhotosoftTM technology, Invion has also reported potential against SARS-CoV-2 virus. In independent tests, Photosoft compounds showed activity against two variants -- Delta and Omicron BA.1. Besides, Invion is also working on treatment of a range of cancers, with at least two clinical trials planned in this ongoing calendar year -- on skin cancer and anogenital cancer. IVX’s lead drug candidate for cancer is INV043.

Invion believes that the findings against MRSA bacteria in the ACARE partnered study are perhaps a corroboration that its technology-driven solutions are proving effective against superbugs. 

Data source: IVX update


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Two ASX Listed Stocks Giving Bullish Indications

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.